Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Long-term outcomes of surgery and radiotherapy for secreting and non-secreting pituitary adenoma

  • Kim, Mi Young (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Jin Hee (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Oh, Young Kee (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, El (Department of Neurosurgery, Dongsan Medical Center, Keimyung University School of Medicine)
  • Received : 2016.02.18
  • Accepted : 2016.03.31
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate treatment outcome and long term complication after surgery and radiotherapy (RT) for pituitary adenoma. Materials and Methods: From 1990 to 2009, 73 patients with surgery and RT for pituitary adenoma were analyzed in this study. Median age was 51 years (range, 25 to 71 years). Median tumor size was 3 cm (range, 1 to 5 cm) with suprasellar (n = 21), cavernous sinus extension (n = 14) or both (n = 5). Hormone secreting tumor was diagnosed in 29 patients; 16 patients with prolactin, 12 patients with growth hormone, and 1 patient with adrenocorticotrophic hormone. Impairment of visual acuity or visual field was presented in 33 patients at first diagnosis. Most patients (n = 64) received RT as postoperative adjuvant setting. Median RT dose was 45 Gy (range, 45 to 59.4 Gy). Results: Median follow-up duration was 8 years (range, 3 to 22 years). In secreting tumors, hormone normalization rate was 55% (16 of 29 patients). For 25 patients with evaluable visual field and visual acuity test, 21 patients (84%) showed improvement of visual disturbance after treatment. The 10-year tumor control rate for non-secreting and secreting adenoma was 100% and 58%, respectively (p < 0.001). Progression free survival rate at 10 years was 98%. Only 1 patient experienced endocrinological recurrence. Following surgery, 60% (n = 44) suffered from pituitary function deficit. Late complication associated with RT was only 1 patient, who developed cataract. Conclusion: Surgery and RT are very effective and safe in hormonal and tumor growth control for secreting and non-secreting pituitary adenoma.

Keywords

References

  1. Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993;38:571-8. https://doi.org/10.1111/j.1365-2265.1993.tb02137.x
  2. Snead FE, Amdur RJ, Morris CG, Mendenhall WM. Long-term outcomes of radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 2008;71:994-8. https://doi.org/10.1016/j.ijrobp.2007.11.057
  3. Sasaki R, Murakami M, Okamoto Y, et al. The efficacy of conventional radiation therapy in the management of pituitary adenoma. Int J Radiat Oncol Biol Phys 2000;47:1337-45. https://doi.org/10.1016/S0360-3016(00)00503-4
  4. Tsang RW, Brierley JD, Panzarella T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ. Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys 1994;30:557-65. https://doi.org/10.1016/0360-3016(92)90941-A
  5. Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol 2009;93:597-601. https://doi.org/10.1016/j.radonc.2009.09.011
  6. Rim CH, Yang DS, Park YJ, Yoon WS, Lee JA, Kim CY. Radiotherapy for pituitary adenomas: long-term outcome and complications. Radiat Oncol J 2011;29:156-63. https://doi.org/10.3857/roj.2011.29.3.156
  7. Brada M, Burchell L, Ashley S, Traish D. The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys 1999;45:693-8. https://doi.org/10.1016/S0360-3016(99)00159-5
  8. Ding D, Starke RM, Sheehan JP. Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy. J Neurooncol 2014;117:445-57. https://doi.org/10.1007/s11060-013-1262-8
  9. Sheplan Olsen LJ, Robles Irizarry L, Chao ST, et al. Radiotherapy for prolactin-secreting pituitary tumors. Pituitary 2012;15:135-45. https://doi.org/10.1007/s11102-011-0348-6
  10. Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000;85:3779-85. https://doi.org/10.1210/jcem.85.10.6870
  11. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006;91:1239-45. https://doi.org/10.1210/jc.2005-1616
  12. Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005;62:210-6. https://doi.org/10.1111/j.1365-2265.2005.02199.x
  13. Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011;96:1992-2003. https://doi.org/10.1210/jc.2011-0251
  14. van den Bergh AC, van den Berg G, Schoorl MA, et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys 2007;67:863-9. https://doi.org/10.1016/j.ijrobp.2006.09.049
  15. Hoybye C, Grenback E, Rahn T, Degerblad M, Thoren M, Hulting AL. Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 2001;49:284-91.
  16. Sattler MG, Vroomen PC, Sluiter WJ, et al. Incidence, causative mechanisms, and anatomic localization of stroke in pituitary adenoma patients treated with postoperative radiation therapy versus surgery alone. Int J Radiat Oncol Biol Phys 2013;87:53-9. https://doi.org/10.1016/j.ijrobp.2013.05.006
  17. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005;90:800-4. https://doi.org/10.1210/jc.2004-1152

Cited by

  1. Updates in outcomes of stereotactic radiation therapy in acromegaly vol.20, pp.1, 2016, https://doi.org/10.1007/s11102-016-0783-5
  2. Evaluation of Complications and Costs During Overlapping Transsphenoidal Surgery in the Treatment of Pituitary Adenoma vol.84, pp.5, 2016, https://doi.org/10.1093/neuros/nyy269
  3. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice vol.161, pp.8, 2016, https://doi.org/10.1210/endocr/bqaa101